The 4th China International Import Expo (CIIE) was held in Shanghai from November 5 to 10.
As one of the first multinational companies to participate in the Expo, Siemens Healthcare has participated in the exhibition for four consecutive years this year, what "black technology" has the company brought this time?
"Ciie is a big stage for the world, and it is a very good opportunity to showcase the latest technological products from all over the world." Huang Yi, vice president of Siemens Medical's imaging diagnosis system in Greater China, said in a face-to-face interview with the "International Finance News" reporter that ultra-high-end pet/ct system for early diagnosis of tumors, photon counting CT technology and other products will be launched at this Expo, and science and technology will benefit mankind. The innovation of medical ecology in the Chinese market is accelerating, especially in the post-epidemic era, Siemens Healthcare will focus on deepening the Chinese market and deepen cooperation in combination with local characteristics.
In the technical equipment exhibition area, Nachi Robot demonstrates the assembly process. (Photo by Liu Hui, a reporter from people's daily)
The "spillover effect" of the Expo is obvious
At the 4th CIIE, what are the highlights of Siemens Healthcare's participation?
Huang Yi told the "International Finance News" reporter that Siemens Medical will show a number of global pioneering technologies at this year's Expo, including an ultra-high-end pet/ct system biograph vision quadra, with its large scanning coverage and ultra-high sensitivity characteristics, it only takes 15 seconds to achieve full-body imaging, and the injection dose can be reduced to up to 1/40 of the conventional, providing a very good means of examination for clinical applications. In addition, the technology displayed at the Expo also includes a photon counting CT technology that has recently been licensed by the US FDA.
Ciie is not only a stage to showcase "black technology", but also a promoter for cooperation and exhibition. As far as Siemens Medical, which has participated in the exhibition for four consecutive years, the "spillover effect" of the Expo is obvious.
Huang Yi introduced to reporters that for the world's first interventional robot - corindus displayed at the last EXPO, the biggest benefit is to bring stronger protection and higher accuracy to interventional surgery, while effectively preventing intraoperative cross-infection, which brings value to doctors and patients. It is precisely because of the appearance of the Expo platform to accelerate the market's attention and recognition, in March 2021 in Hainan Boao Super Hospital to achieve "first to try", in July this year through the State Food and Drug Administration innovative medical device special review application.
In addition, Siemens Medical's "explosive exhibits" at the second Expo- 5G remote ultrasound technology, with the influence of the Expo, its popularity has increased significantly. The breadth and depth of 5G remote diagnosis applications have also been continuously expanded, and the technology has achieved full coverage of large-scale imaging equipment applications under Siemens Healthcare, improving the diagnostic level and skills of grass-roots hospitals in many remote areas.
In the technical equipment exhibition area of the fourth CIIE, visitors experience high-tech instruments. (Photo by Liu Hui, a reporter from the People's Daily)
China's medical innovation has accelerated
Siemens Healthcare's manufacturing and R&D has also taken root in China for 30 years, and in order to further penetrate the Chinese market, Siemens Healthcare has deepened cooperation in combination with the Chinese market. Huang Yi further told this reporter that Siemens Healthcare attaches great importance to the cultivation of talents in scientific research and development teams, and has several major research and development innovation centers in the world. There is also an independent R&D team in China, combined with the characteristics of the local market to innovate, such as the company's high-tech resources and Chinese scientific research institutions to cooperate.
In September 2021, the Siemens Healthers Healthers Shanghai Innovation Center was officially launched, further strengthening cooperation with Chinese start-ups, university researchers and development partners. "Like an incubator, Siemens Healthcare Shanghai Innovation Center provides a lot of software and hardware development environments, as well as professional engineers and technicians, who cooperate with each other to develop original technologies that suit China's national conditions." Huang Yi pointed out.
Behind the innovation, in addition to the investment of talents and funds, Huang Yi said that the integration of the entire ecological chain is also critical. For any high-density medical device technology, a very comprehensive industrial chain foundation is required, and Siemens Healthcare is the only company that can produce the core components of organizational data.
Huang Yi also said that what is more important is the "soil" of the Chinese market, and China's release of policies including the Healthy China 2030 Strategy and the encouragement of medical innovation and research and development provides a good and vast growth market environment. Based on this, businesses and industries thrive.
How innovative has China's medical industry been in recent years?
Huang Yi told reporters bluntly that China is emphasizing the innovative development of intelligent manufacturing and will provide a lot of resource support. As far as the medical industry is concerned, due to the continuous improvement of the technology of ecological partners in other industries, the improvement of supply chain quality has also become the supporting force for innovation of Siemens Healthcare. In the past, scientific research and teaching hospitals stayed more in diagnosis and medical treatment, but now they will do a lot of scientific research and early basic medicine research.
The Chinese market is an important strategic market for Siemens Healthcare, so how to deal with the competition of medical enterprises in the Chinese market?
Huang Yi said frankly that as a multinational enterprise, Siemens Medical is very happy to participate in the rapid development stage of the medical industry with its domestic counterparts, and only in the competition will it progress, "local" enterprises have advantages and characteristics, should have a hundred flowers blooming and see the wisdom of the mentality. "Globalization" is the advantage of Siemens Healthcare, with many global R & D centers, combined with the ability to innovate in the local market, is committed to achieving originality in China, developing products and technologies to serve the world, to achieve true branding and internationalization.
Digitalization is accelerating in the post-pandemic era
Under the influence of the epidemic, the global supply chain has been affected to varying degrees, and the significance of medical intelligence and digital transformation is more important.
The reporter learned that Siemens Medical is also adjusting the industrial layout according to the changes, based on the optimism about the prospects of the Chinese market, Siemens Medical continues to increase the proportion of construction and investment in China.
Huang Yi told the "International Finance News" reporter that Siemens Medical has done many industrial and research and development layouts in China in the past, and under the influence of the epidemic, it is more and more aware that more industrial chain integration will be done in the post-epidemic era. With an investment of about 3 billion yuan, Siemens Healthcare's in vitro diagnostic reagent production base is expected to be put into operation in 2023, which once again confirms Siemens Healthcare's emphasis and confidence in China.
Huang Yi stressed that medical research and development and production technology are increasingly improved, and it is necessary to adhere to the original intention of medical technology for good. In the post-epidemic era, Siemens Healthcare will also target the special needs of China's local market, such as for some remote areas with scarce medical resources, through artificial intelligence and digital technological innovation, breaking the "time and space" restrictions to help achieve use. "Artificial intelligence will not replace doctors, but more to provide important auxiliary means to achieve cost reduction and efficiency."
Reporter: Zhu Denghua
Editor: Chen Kai
Editor-in-Charge: BiDandan